NeuroSense enables near real-time, multimodal monitoring of external ventricular drains in neurocritical care.

NeuroSense Therapeutics is set to participate in the 5th Annual ROTH Healthcare Opportunities Conference, discussing key advancements in neurodegenerative disease treatments.

Epistemic injustice: Autism

Reported Monday, Sep 28 - 6:17am EDT (TheFly subscription required to read more.)

NeuroSense Therapeutics (NRSN) Chief Financial Officer Or Eisenberg will attend the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026.He will meet with institutional investors in New York City. Expected topics include clinical and regulatory progress with PrimeC, its ALS drug candidate, and the company’s strategy toward potential regulatory approval in Canada, the U.S. and other markets.

YouTube video by Epilepsy Sparks Insights

Neurosense Therapeutics said it's producing its ALS therapy PrimeC at a commercial scale as it prepares for potential approval in Canada.

In the fourth episode of Let’s Talk Neurosense, we talked to Katy Elphinstone, autistic advocate, researcher and author of How to Raise Happy Neurofabulous Children: A Parent’s Guide.

NeuroSense Therapeutics provides a comprehensive update on its strategic initiatives and financial outcomes for the first half of 2026, highlighting progress with its ALS therapy, PrimeC.

NeuroSense Therapeutics has announced significant biomarker findings from its Phase 2 Alzheimer's study, supporting its drug PrimeC's multi-target approach.

In the fourth episode of Let’s Talk Neurosense, we talked to Katy Elphinstone, autistic advocate, researcher and author of How to Raise Happy Neurofabulous Children: A Parent’s Guide.

In the fourth episode of Let’s Talk Neurosense, we talked to Katy Elphinstone, autistic advocate, researcher and author of How to Raise Happy Neurofabulous Children: A Parent’s Guide.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

EverythingALS is hosting a vital community event on ALS research featuring NeuroSense. This gathering aims to connect patients, families, and professionals with the latest insights.

NeuroSense Therapeutics has successfully obtained a crucial patent in South Korea for its innovative drug PrimeC, aimed at treating ALS. This milestone enhances its global patent portfolio and supports further clinical studies.